Congenital pseudarthrosis of the tibia can be challenging to treat. A study from 2021 states that, on average, only 50% of surgical procedures for the condition resulted in healing without ...

Congenital Pseudarthrosis of the Tibia (CPT) is a very rare, debilitating and devastating condition. Its incidence is reported to be between 1:140,000 to 1:250,000 live births. Treatment of CPT is ...

in its Phase 1b/2a clinical trial treating four patients with Congenital Pseudarthrosis of Tibia (CPT). Novadip is developing NVD-003, an autologous therapy derived from adipose stem cells (ASC ...

Therefore, the classic term congenital tibial pseudarthrosis used so often in the genetics and orthopedic literature is not the most appropriate term for this progressive process involving the ...

For months, 11-year-old Amit Vigoda has wanted just one thing: to have his right leg amputated. And after a very long decision making process, Amit’s mother and father have agreed to make their ...

an autologous therapy derived from adipose stem cells as a potential single treatment to save limbs and restore mobility in patients with congenital pseudarthrosis of the tibia (CPT), a rare ...

This study was primarily intended to generate safety data in adults prior to initiating pediatric clinical development for the treatment of congenital pseudarthrosis of the tibia, a rare condition ...

Congenital pseudarthrosis of the tibia, or CPT, is a devastating diagnosis. Impacting patients in just .5-3.5 in 150,000 1,2,3 live births, the condition is very rare and debilitating. Treatment ...